Bactericidal Activity of the Combination of Levofloxacin with Rifampin in Experimental Prosthetic Knee Infection in Rabbits Due to Methicillin-susceptible Staphylococcus Aureus

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 2009 Mar 11

PMID 19273687

Citations 6

Authors

Claudette Muller-Serieys

Azzam Saleh Mghir

Laurent Massias

Bruno Fantin

Affiliations

Soon will be listed here.

Abstract

The combination of levofloxacin and rifampin has been recommended for the treatment of staphylococcal prosthetic infection. In a rabbit model of prosthetic knee infection due to a susceptible clinical strain of Staphylococcus aureus, the combination of levofloxacin and rifampin was bactericidal, significantly reduced bacterial titers in bone compared with levels for rifampin and controls (P < 0.05), sterilized 6 of 12 animals, and prevented the selection of resistant mutants that was observed with rifampin alone, validating clinical recommendations.

Citing Articles

Prosthetic Joint Infection Research Models in NZW Rabbits: Opportunities for Standardization-A Systematic Review.

van Agtmaal J, van Hoogstraten S, Arts J J Funct Biomater. 2024; 15(10).

PMID: 39452605 PMC: 11508679. DOI: 10.3390/jfb15100307.

Antibiotics with antibiofilm activity - rifampicin and beyond.

Ferreira L, Pos E, Nogueira D, Ferreira F, Sousa R, Abreu M Front Microbiol. 2024; 15:1435720.

PMID: 39268543 PMC: 11391936. DOI: 10.3389/fmicb.2024.1435720.

Comparison of tolerance between antimicrobial blue light, levofloxacin, and rifampin.

Ong J, Godfrey R, Nazarian A, Tam J, Isaacson B, Pasquina P Front Microbiol. 2023; 14:1158558.

PMID: 37303789 PMC: 10248220. DOI: 10.3389/fmicb.2023.1158558.

Orthopaedic Implant-Associated Staphylococcal Infections: A Critical Reappraisal of Unmet Clinical Needs Associated with the Implementation of the Best Antibiotic Choice.

Gatti M, Barnini S, Guarracino F, Parisio E, Spinicci M, Viaggi B Antibiotics (Basel). 2022; 11(3).

PMID: 35326869 PMC: 8944676. DOI: 10.3390/antibiotics11030406.

Internalization in Osteoblast Cells: Mechanisms, Interactions and Biochemical Processes. What Did We Learn from Experimental Models?.

Stracquadanio S, Musso N, Costantino A, Lazzaro L, Stefani S, Bongiorno D Pathogens. 2021; 10(2).

PMID: 33669789 PMC: 7922271. DOI: 10.3390/pathogens10020239.

References

Cremieux A, Mghir A, Bleton R, Manteau M, Belmatoug N, Massias L . Efficacy of sparfloxacin and autoradiographic diffusion pattern of [14C]Sparfloxacin in experimental Staphylococcus aureus joint prosthesis infection. Antimicrob Agents Chemother. 1996; 40(9):2111-6. PMC: 163482. DOI: 10.1128/AAC.40.9.2111. View

Fantin B, Carbon C . In vivo antibiotic synergism: contribution of animal models. Antimicrob Agents Chemother. 1992; 36(5):907-12. PMC: 188745. DOI: 10.1128/AAC.36.5.907. View

Vaudaux P, Francois P, Bisognano C, Schrenzel J, Lew D . Comparison of levofloxacin, alatrofloxacin, and vancomycin for prophylaxis and treatment of experimental foreign-body-associated infection by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2002; 46(5):1503-9. PMC: 127155. DOI: 10.1128/AAC.46.5.1503-1509.2002. View

Belmatoug N, Cremieux A, Bleton R, Volk A, Saleh-Mghir A, Grossin M . A new model of experimental prosthetic joint infection due to methicillin-resistant Staphylococcus aureus: a microbiologic, histopathologic, and magnetic resonance imaging characterization. J Infect Dis. 1996; 174(2):414-7. DOI: 10.1093/infdis/174.2.414. View

Murillo O, Domenech A, Garcia A, Tubau F, Cabellos C, Gudiol F . Efficacy of high doses of levofloxacin in experimental foreign-body infection by methicillin-susceptible Staphylococcus aureus. Antimicrob Agents Chemother. 2006; 50(12):4011-7. PMC: 1693998. DOI: 10.1128/AAC.00523-06. View

Metallidis S, Topsis D, Nikolaidis J, Alexiadou E, Lazaraki G, Grovaris L . Penetration of moxifloxacin and levofloxacin into cancellous and cortical bone in patients undergoing total hip arthroplasty. J Chemother. 2008; 19(6):682-7. DOI: 10.1179/joc.2007.19.6.682. View

Croom K, Goa K . Levofloxacin: a review of its use in the treatment of bacterial infections in the United States. Drugs. 2003; 63(24):2769-802. DOI: 10.2165/00003495-200363240-00008. View

Lucet J, Herrmann M, Rohner P, Auckenthaler R, Waldvogel F, Lew D . Treatment of experimental foreign body infection caused by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 1990; 34(12):2312-7. PMC: 172053. DOI: 10.1128/AAC.34.12.2312. View

Preston S, Drusano G, BERMAN A, Fowler C, Chow A, Dornseif B . Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA. 1998; 279(2):125-9. DOI: 10.1001/jama.279.2.125. View

10.

Croisier D, Etienne M, Bergoin E, Charles P, Lequeu C, Piroth L . Mutant selection window in levofloxacin and moxifloxacin treatments of experimental pneumococcal pneumonia in a rabbit model of human therapy. Antimicrob Agents Chemother. 2004; 48(5):1699-707. PMC: 400524. DOI: 10.1128/AAC.48.5.1699-1707.2004. View

11.

Chow A, Fowler C, Williams R, Morgan N, Kaminski S, Natarajan J . Safety and pharmacokinetics of multiple 750-milligram doses of intravenous levofloxacin in healthy volunteers. Antimicrob Agents Chemother. 2001; 45(7):2122-5. PMC: 90611. DOI: 10.1128/AAC.45.7.2122-2125.2001. View

12.

NORDEN C . Lessons learned from animal models of osteomyelitis. Rev Infect Dis. 1988; 10(1):103-10. DOI: 10.1093/clinids/10.1.103. View

13.

Blondeau J, Zhao X, Hansen G, Drlica K . Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother. 2001; 45(2):433-8. PMC: 90309. DOI: 10.1128/AAC.45.2.433-438.2001. View

14.

Zimmerli W, Widmer A, Blatter M, Frei R, Ochsner P . Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group. JAMA. 1998; 279(19):1537-41. DOI: 10.1001/jama.279.19.1537. View

15.

Zimmerli W, Trampuz A, Ochsner P . Prosthetic-joint infections. N Engl J Med. 2004; 351(16):1645-54. DOI: 10.1056/NEJMra040181. View

16.

Sendi P, Rohrbach M, Graber P, Frei R, Ochsner P, Zimmerli W . Staphylococcus aureus small colony variants in prosthetic joint infection. Clin Infect Dis. 2006; 43(8):961-7. DOI: 10.1086/507633. View

17.

Chuard C, Herrmann M, Vaudaux P, Waldvogel F, Lew D . Successful therapy of experimental chronic foreign-body infection due to methicillin-resistant Staphylococcus aureus by antimicrobial combinations. Antimicrob Agents Chemother. 1991; 35(12):2611-6. PMC: 245440. DOI: 10.1128/AAC.35.12.2611. View

18.

Drancourt M, Stein A, Argenson J, Zannier A, Curvale G, Raoult D . Oral rifampin plus ofloxacin for treatment of Staphylococcus-infected orthopedic implants. Antimicrob Agents Chemother. 1993; 37(6):1214-8. PMC: 187942. DOI: 10.1128/AAC.37.6.1214. View

19.

Zarrouk V, Bozdogan B, Leclercq R, Garry L, Feger C, Carbon C . Activities of the combination of quinupristin-dalfopristin with rifampin in vitro and in experimental endocarditis due to Staphylococcus aureus strains with various phenotypes of resistance to macrolide-lincosamide-streptogramin antibiotics. Antimicrob Agents Chemother. 2001; 45(4):1244-8. PMC: 90450. DOI: 10.1128/AAC.45.4.1244-1248.2001. View